Evidence map›Paper›PMID 34641562›Full record

ArticleMolecules (Basel, Switzerland)2021

Patient-Derived Tumor Chemosensitization of GKB202, an

Tsung-Ju Li, Ting-Wei Lin, Shih-Pei Wu, Hsin-Tung Chu, Yu-Hsuan Kuo, Jeng-Fong Chiou, Long-Sheng Lu, Chin-Chu Chen

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Targeting alternative splicing in cancer immunotherapy.Frontiers in cell and developmental biology · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tsung-Ju LiBiotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan.
Ting-Wei LinBiotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan.
Shih-Pei WuCancerFree Biotech Ltd., Taipei City 106, Taiwan.
Hsin-Tung ChuBiotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan.
Yu-Hsuan KuoBiotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan.
Jeng-Fong ChiouDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, Taiwan.
Long-Sheng LuDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, Taiwan.ORCID 0000-0002-4247-1981
Chin-Chu ChenBiotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan.

Funding

Ministry of Science and Technology, Taiwan MOST-109-2314-B-038-122Taipei Medical University TMU-DP2-110-21121-03-C-06-02
6 · The paper itself

Abstract

Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficiently expands CTC from patients to test

Indexed as

AdultAgedAnimalsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularColorectal NeoplasmsFemaleFluorouracilHumansMaleMiddle AgedMyceliumOrganoidsPolyporalesRatsTumor Cells, CulturedFluorouracil5-FUACMAntrodia Cinnamomea myceliumcirculating tumor cellspatient-derived organoid

Identifiers

PMID34641562
PMCPMC8512555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.